4.7 Article

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence

Related references

Note: Only part of the references are listed.
Article Psychology, Multidisciplinary

Scanxiety and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up-a qualitative study

Katharina Seibel et al.

Summary: Anxiety surrounding follow-up scans, also known as scanxiety, is a common problem for lung cancer survivors and caregivers. However, follow-up care can also bring a sense of security and control, which can improve the psychological well-being of the survivors and their families. In order to improve the quality of life of lung cancer survivors and caregivers, future strategies should focus on integrating psychosocial care, such as the introduction of survivorship care plans or increased use of patient-reported outcomes.

BMC PSYCHOLOGY (2023)

Article Surgery

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras

Michael J. Cavnar et al.

Summary: Surgery for gastrointestinal stromal tumor (GIST) in the imatinib era has resulted in prolonged overall survival compared to the pre-imatinib era. Tumor site, size, and mitotic rate in pre-imatinib era primary tumor patients are associated with survival. Imatinib treatment may benefit patients with high-risk features, particularly tumor size.

ANNALS OF SURGERY (2021)

Article Oncology

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)

P. G. Casali et al.

Summary: In 2004, a randomized trial comparing adjuvant imatinib to no further therapy for GIST patients was initiated. The final results, with a median follow-up of 9.1 years, showed a potential trend towards better long-term outcomes with imatinib treatment in high-risk patients.

ANNALS OF ONCOLOGY (2021)

Review Medicine, General & Internal

Scanxiety: a scoping review about scan-associated anxiety

Kim Tam Bui et al.

Summary: The prevalence and severity of scanxiety varied widely in the studies due to heterogeneous measurement methods. A uniform approach to assessing scanxiety is needed to improve understanding of the phenomenon and guide interventions.

BMJ OPEN (2021)

Article Oncology

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour

Lorenzo D'Ambrosio et al.

EUROPEAN JOURNAL OF CANCER (2017)

Article Psychology, Clinical

The cross-national epidemiology of specific phobia in the World Mental Health Surveys

K. J. Wardenaar et al.

PSYCHOLOGICAL MEDICINE (2017)

Article Oncology

Untitled

JOURNAL OF SURGICAL ONCOLOGY (2016)

Article Oncology

KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

Heikki Joensuu et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Article Medicine, General & Internal

Answers to Common Questions About the Use and Safety of CT Scans

Cynthia H. McCollough et al.

MAYO CLINIC PROCEEDINGS (2015)

Editorial Material Oncology

Rational Follow-Up After Curative Cancer Resection

Matthew J. Furman et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Article Medicine, General & Internal

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial

Heikki Joensuu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)

Article Medical Laboratory Technology

Gastrointestinal stromal tumors: Pathology and prognosis at different sites

Markku Miettinen et al.

SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)